title: Antidiuretic action of tachykinin NK-3 receptor in the rat paraventricular nucleus.
abstract: Studies were performed on the central antidiuretic actions via the tachykinin NK-3 receptor in the rat hypothalamic paraventricular nucleus (PVN). Microinjections of the selective tachykinin NK-3 receptor agonist senktide (2-200 pmol) into the PVN resulted in prolonged inhibition of urine output in water-loaded rats, its effect being dose-dependent. The antidiuretic action of senktide was blocked by pretreatment with the vasopressin V2 receptor antagonist OPC-31260 (1 mg/kg, i.v.), but not by microinjection of the angiotensin II AT-1 receptor antagonist losartan (1 nmol) into the PVN. NK-3 receptor mRNA was strongly detected in the magnocellular part of the PVN and the supraoptic nucleus (SON) of the hypothalamus as detected by in situ hybridization histochemistry. Moreover, [3H]senktide binding sites were also detected in the PVN and the SON by receptor autoradiography. These findings suggest that NK-3 receptors in the PVN may be involved in water regulation by stimulation of vasopressin secretion from the posterior pituitary gland, and that vasopressin caused water reabsorbtion via the kidney V2 receptor.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Eguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Takano
authors.forename: T
authors.initials: T
authors.lastname: Hatae
authors.forename: R
authors.initials: R
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Y
authors.initials: Y
authors.lastname: Shigeyoshi
authors.forename: H
authors.initials: H
authors.lastname: Okamura
authors.forename: J E
authors.initials: JE
authors.lastname: Krause
authors.forename: H
authors.initials: H
authors.lastname: Kamiya
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001713:Biphenyl Compounds / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects / Q000502:physiology*; D007093:Imidazoles / Q000494:pharmacology; D019808:Losartan; D008297:Male; D008845:Microinjections; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1; D018042:Receptors, Neurokinin-3 / Q000819:agonists / Q000502:physiology*; D017483:Receptors, Vasopressin / Q000502:physiology; D012995:Solubility; D013373:Substance P / Q000031:analogs & derivatives* / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology; D014556:Urine
chemical_list: D057911:Angiotensin Receptor Antagonists; D065092:Antidiuretic Hormone Receptor Antagonists; D001713:Biphenyl Compounds; D007093:Imidazoles; D010446:Peptide Fragments; D044140:Receptor, Angiotensin, Type 1; D018042:Receptors, Neurokinin-3; D017483:Receptors, Vasopressin; D013777:Tetrazoles; C054724:senktide; D013373:Substance P; D019808:Losartan